B-cell receptor and antibody recognizing Streptococcus pneumoniae polysaccharide antigen

B-cell receptors (BCRs) and antibodies recognizing Streptococcus pneumoniae polysaccharide antigens are central mediators of humoral immunity against encapsulated pneumococci. The BCR, a membrane-bound immunoglobulin on B cells, specifically binds capsular polysaccharides from S. pneumoniae, initiating B-cell activation and differentiation into plasma cells that secrete antibodies. These antibodies, especially IgM and IgG, opsonize bacteria, trigger complement activation, and enable phagocytic clearance by immune cells. Natural and vaccine-induced antibody responses to polysaccharide antigens are often T-cell independent (rapid, but with limited affinity maturation and memory), though conjugate vaccines can elicit T-cell dependent responses with robust memory. These immune targets are essential for protection against pneumococcal disease and form the mechanistic basis for licensed polysaccharide and conjugate vaccines. Impaired B-cell or antibody function (e.g., in children, the elderly, immunodeficient states) increases susceptibility to pneumococcal infection, highlighting their value as both therapeutic targets and clinical biomarkers. The same molecular pathways represent potential avenues for monoclonal antibody therapies for invasive pneumococcal diseases.

Other names

Polysaccharide-specific B-cell receptorAnti-pneumococcal polysaccharide antibodyPneumococcal capsular polysaccharide B-cell receptorPneumococcal PS antibody

Induction and binding of B-cell receptors to polysaccharide antigens leads to B-cell activation, differentiation into plasma cells, and antibody secretion; Antibodies opsonize S. pneumoniae for phagocytosis by immune cells; Antibodies activate complement pathways leading to enhanced bacterial killing; Vaccines stimulate specific B-cell clones that secrete protective antibodies against capsular polysaccharides